Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Bullboard Posts
Post by somweyungguyon Oct 04, 2016 6:59am
268 Views
Post# 25305631

Money in confusion and misleading numbers?

Money in confusion and misleading numbers?Yesterday's news release was a complete joke.

It made little to no sense, and different versions landed in different places.

The analysis by the FDA is to be done on the last 176 patients for primary 28 day mortality.

Where is this number in plain english?

The advertised 45% composite mortality rate was for the same 176 patient poulation.

Why was it left without that description in the presentation?

Corrections were made to the presentation ( .06 EAA to .6 in 2 places ) after the 45% was in question.  

Why wasn't it clarified by the company in the presentation

Similar misleading errors were made on the PAID FOR Zacks report and NOT clarified either

I smell too much drama...see Josh posting a 1/2 dozen posts before 7am

Sqr
Bullboard Posts